Investors purchased shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) on weakness during trading hours on Monday. $126.14 million flowed into the stock on the tick-up and $116.15 million flowed out of the stock on the tick-down, for a money net flow of $9.99 million into the stock. Of all companies tracked, Teva Pharmaceutical Industries had the 27th highest net in-flow for the day. Teva Pharmaceutical Industries traded down ($0.09) for the day and closed at $18.52

Several equities research analysts have issued reports on the stock. TheStreet cut shares of Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. ValuEngine cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Evercore ISI set a $38.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday, October 26th. Finally, Credit Suisse Group cut shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $25.00 to $13.00 in a research note on Wednesday, August 23rd. Five equities research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $20.68.

The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The company has a market cap of $18,816.32, a PE ratio of 4.28 and a beta of 0.55.

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were given a $0.085 dividend. The ex-dividend date was Monday, November 27th. This represents a $0.34 annualized dividend and a dividend yield of 1.94%. Teva Pharmaceutical Industries’s dividend payout ratio is presently -12.10%.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital Research Global Investors boosted its position in shares of Teva Pharmaceutical Industries by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after acquiring an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. lifted its position in Teva Pharmaceutical Industries by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after buying an additional 6,685,844 shares in the last quarter. FMR LLC lifted its position in Teva Pharmaceutical Industries by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after buying an additional 6,115,853 shares in the last quarter. Northern Cross LLC lifted its position in Teva Pharmaceutical Industries by 14.0% during the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after buying an additional 2,184,172 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in Teva Pharmaceutical Industries by 2.5% during the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after buying an additional 311,894 shares in the last quarter. 51.98% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Traders Buy Teva Pharmaceutical Industries (TEVA) on Weakness” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/traders-buy-teva-pharmaceutical-industries-teva-on-weakness/1774738.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.